Status:
RECRUITING
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Collaborating Sponsors:
Beijing Children's Hospital
Tianjin People's Hospital
Conditions:
Primary Immune Thrombocytopenia
Eligibility:
All Genders
6-17 years
Brief Summary
Immune thrombocytopenic purpura (ITP) is a kind of rare childhood disease that involve autoimmune destruction of platelets.The current Pediatric ITP cohorts are mostly based on single-center or multi-...
Detailed Description
Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease, which is characterized by decreased platelet count and skin and mucosal bleeding. ITP is a kind of disease with increased platele...
Eligibility Criteria
Inclusion
- Age 6-17 years old (including both ends), male and female;
- Diagnosis of ITP.
Exclusion
- Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.;
- The expected follow-up period is less than 3 months.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2036
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06107582
Start Date
November 1 2023
End Date
December 1 2036
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese Academy of Medical Science and Blood Disease Hospital
Tianjin, China, 300020